GHRP-6
Mechanism of Action, Benefits, Dosing Protocols and Safety Guide
GHRP-6 is a synthetic peptide that stimulates your pituitary gland to release growth hormone (GH) in natural, pulsatile bursts. Bodybuilders use it for muscle growth and recovery, anti-aging researchers study it for its preserved response in older adults, and preclinical scientists are investigating its potential cardioprotective properties. The human evidence for GH stimulation is solid — the evidence for everything else is largely animal data, and the peptide is not approved by any major regulatory authority.
Key takeaways
- GHRP-6 binds the ghrelin receptor (GHS-R1a) to trigger pulsatile GH release. This mechanism differs entirely from GHRH analogs, which is why combining the two produces 3–4× more GH than either alone.
- At the optimal dose of 1 mcg/kg IV, peak GH reached 33.8 mcg/L in healthy men (Pandya et al., 1998, PMID 9543138).
- Unlike GHRH-stimulated GH release, GHRP-6’s GH response does not decline with age (Popovic et al., 1995, PMID 7734029).
- Doses above 100–200 mcg do not proportionally increase GH output — they primarily raise cortisol and prolactin instead.
- GHRP-6 is not FDA-approved and is explicitly prohibited by WADA under S2.2 at all times.
Before you start All peptide protocols require a physician evaluation. GHRP-6 affects cortisol, prolactin, blood glucose, and GH/IGF-1 simultaneously — baseline bloodwork is important before starting any protocol.
What is GHRP-6?
GHRP-6 — Growth Hormone-Releasing Peptide 6 — is a synthetic hexapeptide (six amino acids) with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. Its molecular weight is 873.01 g/mol.
Cyril Y. Bowers developed GHRP-6 in 1981 while working on synthetic enkephalin analogues. The GH-releasing effect was unexpected — a discovery that launched an entire class of compounds now called Growth Hormone Secretagogues (GHS).
Two D-amino acids in the structure (at positions 2 and 5) give GHRP-6 resistance to enzymatic breakdown. This is why injectable GHRP-6 holds up in the body while natural peptides are degraded rapidly.
Learn more about how GHRP-6 compares to other growth hormone secretagogues.
How does GHRP-6 work?
GHRP-6 works by binding to two distinct receptors in your body. Understanding which receptor does what explains both the GH-releasing effects and the organ-protective properties researchers have observed in animal models.
Two receptors, two mechanisms
The primary target is GHS-R1a (the ghrelin receptor), located on neurons in the hypothalamic arcuate nucleus and on somatotroph cells in the anterior pituitary. This is the receptor responsible for GH release and appetite stimulation.
GHRP-6 also binds CD36, a scavenger receptor. CD36 activation mediates cardioprotective and wound-healing effects that appear independent of GH signaling — which is why GHRP-6 shows organ-protective effects in animal models even when GH signaling is blocked.
The GH signaling chain
When GHRP-6 binds GHS-R1a, the following sequence occurs:
GHS-R1a activation → Phospholipase C (PLC) activation → PI breaks into IP3 + DAG → IP3 releases intracellular calcium → DAG activates Protein Kinase C (PKC) → PKC + calcium trigger GH secretion from somatotroph cells
Lei et al. (1995, PMID 7772238) confirmed this mechanism in human pituitary somatotrophinoma cells. Across all eight tumors tested, GHRP-6 stimulated phosphatidylinositol (PI) turnover by 2.1 to 7.9-fold, with GH secretion rising in parallel. Effects appeared within 15 minutes and peaked at two hours.
Why GHRP-6 and GHRH analogs work better together
GHRH (growth hormone-releasing hormone) stimulates GH through a completely different pathway: cAMP and protein kinase A (PKA). GHRP-6 does not activate cAMP at all.
This means two different receptors activate two different signaling cascades in the same somatotroph cells when you combine GHRP-6 with a GHRH analog like CJC-1295. The result is documented synergistic GH amplification — 3–4× more GH than either peptide alone (Teichman et al., 2006, PMID 16352683).
Pandya et al. (1998) confirmed the interdependence: blocking endogenous GHRH with a specific antagonist reduced the GH response to GHRP-6 by 82%. Endogenous GHRH is needed for GHRP-6 to achieve its maximum effect.
Learn more about GHRP-6 stacking protocols and synergistic GH amplification.
What does the research show?
Key takeaways — research
- Human pharmacokinetic data (Cabrales et al., 2012, PMID 23099431) shows a distribution half-life of 7.6 minutes and elimination half-life of 2.5 hours in nine healthy male volunteers.
- GHRP-6’s GH-releasing effect is Grade A evidence (multiple human studies, consistent results). Cardioprotection and organ protection are Grade C (primarily animal data).
- In a porcine myocardial infarction model, GHRP-6 rescued over 70% of ischemic myocardium from cell death.
- No human RCT exists for any injury recovery application — tendon, ligament, rotator cuff, or otherwise.
GH stimulation and anti-aging
This is where the human evidence is strongest.
Pandya et al. (1998, PMID 9543138) demonstrated peak GH of 33.8 ± 4.8 mcg/L at 1 mcg/kg IV in healthy men. The response is dose-dependent but plateaus: higher doses produce diminishing GH returns and rising cortisol.
The anti-aging finding comes from Popovic et al. (1995, PMID 7734029). Unlike the GHRH-stimulated GH response — which declines measurably with age — GHRP-6’s GH response is preserved in older adults. This finding suggests that age-related GH decline may reflect a functional, potentially reversible state rather than permanent loss of pituitary capacity.
PeptideRx rates the evidence for GHRP-6’s GH-releasing effects as Grade A: multiple human studies with consistent results demonstrating dose-dependent GH secretion.
Cardiovascular and cardioprotection
GHRP-6 shows striking results in preclinical cardiac models — though no human cardiovascular trials have been conducted.
In a porcine model of acute myocardial infarction (left circumflex artery occlusion for one hour, followed by 72 hours of reperfusion), GHRP-6 rescued over 70% of ischemic myocardium from cell death. The mechanism involves dual CD36 and GHS-R1a receptor activation, upregulation of the PI3K/Akt/Bcl-2 survival pathway, reduced reactive oxygen species, and preserved antioxidant defenses.
Berlanga-Acosta et al. (2024, PMID 38873581) reported preserved ejection fraction and reduced mortality in a doxorubicin-induced cardiomyopathy model. GHRP-6 produced a transient increase in ejection fraction of 15–20% within 15 minutes of IV administration.
Data gap: These are animal models. No human cardiovascular trial has been conducted with GHRP-6.
PeptideRx rates the evidence for GHRP-6 cardioprotection as Grade C: primarily animal and preclinical data.
Appetite stimulation
This is a well-documented human effect. Frieboes et al. (1999, PMID 10336729) confirmed appetite stimulation via hypothalamic GHS-R1a activation, with onset at 15–30 minutes post-injection and duration of approximately 30–60 minutes.
The appetite effect is a benefit for individuals trying to gain weight or muscle, and a drawback for those focused on fat loss.
Gut protection and neuroprotection
Granado et al. (2005, PMID 16417467) reported that GHRP-6 at 120 mcg/kg reduced hepatic and intestinal damage by 50–85% and reduced neutrophilic infiltration in a rat ischemia/reperfusion model. The mechanism appears to involve gastric epithelial cell survival signaling.
In neurological animal models, GHRP-6 increased IGF-1 mRNA in the hypothalamus, cerebellum, and hippocampus, activating PI3K/Akt cell survival pathways and increasing Bcl-2 (an anti-apoptotic protein) expression.
Data gap: No human trials exist for IBS, IBD, traumatic brain injury, Parkinson’s disease, or cognitive function applications.
Musculoskeletal and wound healing
The GH cascade is well-established in humans: GH stimulates IGF-1 production in the liver, and IGF-1 promotes muscle protein synthesis and lipolysis. GHRP-6 reliably stimulates this cascade. Animal studies show improved body composition, wound closure, and collagen organization through CD36-mediated angiogenesis and anti-fibrotic TGF-β1/CTGF downregulation.
Data gap: No human RCT exists for GHRP-6’s effects on tendon repair, rotator cuff, plantar fasciitis, or meniscus injuries. Community reports of injury recovery are anecdotal.
Learn more about GHRP-6 evidence grades and data gaps.
Dosing and administration
Important: All dosing information below reflects published research protocols and community-reported practices. This is not a prescribing recommendation. Consult a licensed physician before starting any protocol.
Subcutaneous injection is the only route supported by published research. Frieboes et al. (1999) confirmed that oral GHRP-6 at 300 mcg/kg produced no GH response in adults due to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and first-pass liver metabolism. An effective oral dose would theoretically require 20,000–40,000 mcg versus 100–300 mcg injectable.
The saturation dose concept: 100 mcg per injection produces a near-maximal GH pulse. Going above 100–200 mcg does not proportionally increase GH output — it primarily raises cortisol and prolactin. Pandya et al. (1998) confirmed that the highest GH peak came at a moderate dose, not the maximum dose tested.
Food timing matters: Insulin and elevated blood glucose suppress GH secretion. Fast for a minimum of two hours before each injection. Wait 20–30 minutes after injection before eating. The appetite surge (onset 15–30 minutes) makes this waiting period challenging.
Dosing protocols by goal
| Goal | Dose per injection | Frequency | Cycle duration | Timing notes |
|---|---|---|---|---|
| Anti-aging / general wellness | 100 mcg SC | 1–2× daily | 8–12 weeks on, 4–8 weeks off | Morning fasted + before bed |
| Muscle growth / body composition | 100–200 mcg SC | 2–3× daily | 12–16 weeks on, 4–8 weeks off | Fasted; pre-workout + before bed |
| Fat loss | 100 mcg SC | 2–3× daily | 8–12 weeks on, 4 weeks off | Appetite surge may work against fat-loss goals |
| Injury recovery | 100–200 mcg SC | 2–3× daily | 8–12 weeks or until goal | Often combined with BPC-157 or TB-500 |
| Sleep optimization | 100 mcg SC | 1× daily (bedtime) | 8–12 weeks on, 4 weeks off | 30 min before sleep, fasted |
Administration routes compared
| Route | Approximate bioavailability | Typical dose | Evidence level | Notes |
|---|---|---|---|---|
| Subcutaneous injection | ~100% | 100–300 mcg | Human clinical trials | Gold standard; most predictable absorption |
| Intramuscular injection | ~100% | 100–300 mcg | Human clinical trials | Similar to SC; less common in practice |
| Intranasal | Moderate (~10–30× dose vs injectable) | 3,000–10,000 mcg | Limited human data (Frieboes, 1999) | Variable absorption; alternative for needle-averse users |
| Oral | <1% | Not practical | Human data (no GH response at 300 mcg/kg) | DPP-4 degradation + first-pass metabolism |
| Sublingual | Very low | Not established | No published data | Not effective for peptides of this size |
| Topical | None established | N/A | No data | No evidence of systemic absorption |
Reconstitution guide
| Vial size | Bacteriostatic water | Concentration | 100 mcg dose | 200 mcg dose | 300 mcg dose |
|---|---|---|---|---|---|
| 5 mg | 2.5 mL | 2,000 mcg/mL | 5 units (U-100 syringe) | 10 units | 15 units |
| 5 mg | 5.0 mL | 1,000 mcg/mL | 10 units | 20 units | 30 units |
| 10 mg | 5.0 mL | 2,000 mcg/mL | 5 units | 10 units | 15 units |
Reconstitution steps:
Inject bacteriostatic water slowly down the inner wall of the vial. Never spray directly onto the lyophilized powder. Swirl gently until dissolved — never shake, as shaking can denature the peptide and reduce activity. For a standard 5 mg vial with 2.5 mL bacteriostatic water, the resulting concentration is 2,000 mcg/mL. Five units on a U-100 insulin syringe equals 100 mcg.
Storage:
- Lyophilized (unreconstituted): –20°C for long-term storage (stable 18–36 months). Room temperature shipping is acceptable for short periods.
- Reconstituted with bacteriostatic water: Refrigerate at 2–8°C. Use within 14–21 days (per CDC multi-dose vial guidance).
- Reconstituted with sterile water: Refrigerate at 2–8°C. Use within 3–5 days (no preservative present).
- Protect from light. Never freeze reconstituted peptide.
Injection technique: Use a 29–31 gauge insulin syringe. Pinch a fold of skin at the injection site. Insert the needle at a 45–90 degree angle. Inject slowly. Hold for 3–5 seconds before withdrawing. Aspiration is not required for subcutaneous injections.
Injection site rotation: Rotate between the abdomen (most common, 2 inches from the navel), upper thigh, and back of the arm. Rotate daily to prevent lipohypertrophy.
Learn more about GHRP-6 reconstitution, storage, and injection technique.
Stacking GHRP-6
| Stack partner | Synergy rationale | Evidence level | Typical dosing combination |
|---|---|---|---|
| CJC-1295 No DAC (Mod GRF 1-29) | Different receptor pathways (GHS-R1a + GHRHR); 3–4× synergistic GH amplification | Human synergy data | 100 mcg each, 2–3× daily, fasted |
| CJC-1295 with DAC | Sustained GHRHR activation; once-weekly dosing | Human GH data | 2 mg CJC-1295 DAC weekly + 100 mcg GHRP-6 2–3× daily |
| BPC-157 | Localized tissue repair + systemic GH signaling | Animal data for BPC-157; human GH data for GHRP-6 | BPC-157 250–500 mcg 1–2× daily + GHRP-6 100 mcg 2–3× daily |
| TB-500 | Tissue remodeling + systemic GH cascade | Animal data | TB-500 loading phase + GHRP-6 standard protocol |
| Sermorelin | GHRH analog; similar synergy logic to CJC-1295 | Human data | Sermorelin 200–300 mcg + GHRP-6 100 mcg before bed |
Gold-standard stack: GHRP-6 + CJC-1295 No DAC. GHRP-6 activates GHS-R1a (PI/PKC/calcium pathway); CJC-1295 No DAC activates GHRHR (cAMP/PKA pathway). Different receptors, different signaling cascades, documented synergistic GH amplification (Teichman et al., 2006, PMID 16352683). Draw CJC-1295 into the syringe first, then GHRP-6. Both can be injected together in the same syringe.
CJC-1295 No DAC vs DAC: The No DAC version (also called Mod GRF 1-29) has a short half-life and is dosed 2–3× daily alongside GHRP-6. The DAC version uses a much longer half-life, dosed once weekly, which creates sustained non-pulsatile GHRH receptor activation. Most practitioners prefer No DAC for preserving natural pulsatile GH release patterns.
Confirmed safe combination: Metoprolol (beta-blocker) has no documented interaction with GHRP-6.
Contraindicated combinations: Active cancer (GH/IGF-1 promote cell proliferation), insulin and diabetes medications (glucose metabolism interaction), and corticosteroids (HPA axis interference). No formal drug interaction studies have been conducted for GHRP-6 with any medication.
Learn more about GHRP-6 stacks and combination protocols.
Side effects and safety
Key takeaways — safety
- Appetite surge is the most commonly reported effect. Onset is 15–30 minutes post-injection; duration is 30–60 minutes.
- Cortisol and prolactin elevation follow a dose threshold: minimal at or below 100 mcg; noticeable above 100–200 mcg (Frieboes et al., 1999).
- Absolute contraindications include active cancer, pregnancy, and known or suspected pituitary tumors (without endocrinologist supervision).
- No human safety data exists beyond short-term clinical trials.
Documented side effects
| Side effect | Dose threshold | Onset | Notes |
|---|---|---|---|
| Appetite surge | All doses | 15–30 min post-injection | Duration ~30–60 min; beneficial for bulking/cachexia; problematic for fat loss |
| Water retention (mild) | GH-mediated | Gradual | Resolves after stopping |
| Cortisol elevation | >100–200 mcg | Follows GH peak | May interfere with sleep and stress recovery |
| Prolactin elevation | >100–200 mcg | Follows GH peak | Rare: gynecomastia in men, lactation (very rare); manageable with cabergoline or vitamin B6 |
| Carpal tunnel-like symptoms / joint discomfort | GH-mediated | Gradual | Typically resolves with dose reduction |
| Injection site reactions | All doses | Immediate | Redness, mild irritation; rotate sites |
Serious safety concerns
Cancer: GH and IGF-1 promote cell proliferation. CD36 mediates angiogenesis. Lei et al. (1995) showed GHRP-6 stimulates GH secretion in human somatotrophinoma cells. No human clinical trial has confirmed GHRP-6 causes or accelerates cancer. Absolute contraindication: do not use with active cancer or history of hormone-sensitive malignancy.
Pregnancy: Absolute contraindication. No safety data exists for fetal exposure.
Diabetes: Animal studies show worsened glucose tolerance and altered pancreatic morphology. Anyone with type 1 or type 2 diabetes should monitor blood glucose closely. GH antagonizes insulin, which may require medication adjustments under physician supervision.
Cardiovascular: GHRP-6 produces an acute inotropic effect within 15 minutes. While preclinical data shows cardioprotection, the inotropic response warrants caution in individuals with active heart conditions, arrhythmias, or uncontrolled hypertension.
Pituitary tumors: GHRP-6 stimulates GH secretion in pituitary adenomas (Lei, 1995). Do not use without endocrinologist supervision if a pituitary tumor is known or suspected.
Important: Long-term human safety data does not exist for GHRP-6. No studies have evaluated repeated administration effects on the pituitary, adrenal axis, glucose metabolism, or cancer risk over extended periods.
Learn more about GHRP-6 side effects, contraindications, and monitoring.
Legal status (2026)
| Jurisdiction | Regulatory status | Prescription pathway | Possession | Sale |
|---|---|---|---|---|
| United States | Not FDA-approved; unapproved drug under FD&C Act | Compounding legality unclear (absent from 503A Bulks List) | Low enforcement risk | Research chemical (“not for human use”) |
| European Union | Not approved by EMA | Varies by country | Generally low risk | Research chemical |
| United Kingdom | Not approved by MHRA | Limited | Generally low risk | Research chemical |
| Canada | Not approved by Health Canada | Compounding varies by province | Generally low risk | Research chemical |
| Australia | Not approved by TGA | Schedule 4 (prescription only) | More restrictive | Regulated |
WADA status: Prohibited at all times under S2.2 (Growth Hormone Secretagogues) on the 2025–2026 Prohibited List. The prohibition applies both in-competition and out-of-competition. A positive test carries a 2–4 year ban for a first offense. Competitive athletes subject to WADA or USADA testing must not use GHRP-6.
Important: GHRP-6 is absent from the FDA’s 503A Compounding Bulks List per analysis by Frier Levitt (2025). The legality of compounding GHRP-6 under Section 503A is unresolved under current FDA guidance. “Research Use Only” labels on peptide products do not provide legal protection for human use.
Standard military urinalysis does not test for GHRP-6. Expanded testing is possible if GH doping is specifically suspected.
Learn more about the regulatory status of growth hormone secretagogues in 2026.
Alternatives to GHRP-6
| Peptide | GH output (relative) | Appetite effect | Cortisol/prolactin | Primary route | Evidence base | Best for |
|---|---|---|---|---|---|---|
| GHRP-6 | Moderate-high | Strong (onset 15–30 min) | Dose-dependent (>100 mcg) | SC injection 2–3× daily | Human clinical trials | Bulking; appetite stimulation desired; CD36 cardioprotection research |
| GHRP-2 | High (highest per-dose GH) | Moderate (less than GHRP-6) | Moderate | SC injection 2–3× daily | Human clinical trials | Maximum GH output with less appetite disruption |
| Ipamorelin | Moderate | Minimal | Minimal | SC injection 2–3× daily | Human clinical trials | Clean GH profile; fat loss; long-term use; minimal side effects |
| Hexarelin | Highest single-dose GH | Moderate | Moderate-high | SC injection | Human data | Short-term maximum GH; rapid desensitization limits chronic use |
| CJC-1295 No DAC | Moderate (GHRH pathway) | None direct | Minimal | SC injection 2–3× daily | Human data | Best combined with a GHRP for synergistic GH amplification |
| Sermorelin | Moderate (GHRH analog) | None direct | Minimal | SC injection daily | Human trials | Prescription pathway preference; GHRH-specific stimulation |
| MK-677 (Ibutamoren) | Moderate-high (sustained) | Strong | Moderate; insulin resistance risk | Oral once daily | Human clinical trials | Needle-averse users; accept insulin resistance trade-off |
Decision logic:
Choose Ipamorelin for the cleanest side effect profile — minimal cortisol, prolactin, and appetite effects — making it the preferred option for fat loss or long-term protocols.
Choose GHRP-2 for the highest GH output per dose with less appetite disruption than GHRP-6, suitable for cutting phases.
Choose GHRP-6 when appetite stimulation is a benefit (bulking, cachexia recovery) or when CD36-mediated cardioprotective effects are a research interest.
Choose MK-677 for oral convenience, accepting the trade-off of insulin resistance risk and non-pulsatile GH elevation.
Learn more about how GHRP-6 compares to Ipamorelin and GHRP-2.
The bottom line
GHRP-6 has real, well-documented human evidence for GH stimulation — the Grade A evidence here is not in dispute. The finding that its GH response is preserved with age (Popovic et al., 1995) is genuinely relevant if you’re exploring GH optimization in your 40s or 50s. The cardioprotective and tissue repair data are intriguing but remain animal-model results; no human trials have tested these applications. If you’re considering any GH secretagogue, your first step is bloodwork — GH, IGF-1, glucose, and prolactin at minimum — and a conversation with a licensed physician who understands where the evidence actually ends.
Frequently asked questions
How does GHRP-6 stimulate growth hormone release?
GHRP-6 binds the ghrelin receptor (GHS-R1a) at the hypothalamus and pituitary, which activates phospholipase C and triggers a signaling chain involving IP3 and DAG. IP3 releases intracellular calcium, DAG activates Protein Kinase C (PKC), and PKC plus calcium together drive GH secretion from somatotroph cells. The entire process runs independently of the cAMP pathway that GHRH uses — which is why combining both produces synergistic GH amplification.
How does GHRP-6 compare to GHRP-2 and Ipamorelin?
GHRP-2 produces the highest GH output per dose with less appetite stimulation than GHRP-6. Ipamorelin is the most selective option, with minimal cortisol, prolactin, and appetite effects, making it preferable for fat loss or long-term use. GHRP-6 is the better choice when appetite stimulation is a benefit — during bulking, for example — or when the CD36 cardioprotective mechanism is of research interest.
What is the correct way to reconstitute GHRP-6?
Add bacteriostatic water slowly down the vial wall — never spray directly onto the powder, and never shake. A standard ratio of 5 mg + 2.5 mL produces 2,000 mcg/mL concentration (5 units on a U-100 syringe = 100 mcg). Refrigerate at 2–8°C after reconstitution and use within 14–21 days.
Is GHRP-6 banned in sports?
Yes — GHRP-6 is explicitly named on the WADA 2025–2026 Prohibited List under S2.2 (Growth Hormone Secretagogues). The prohibition applies at all times, both in-competition and out-of-competition. A positive test carries a 2–4 year ban for a first offense.
What are the most common GHRP-6 side effects?
The most commonly reported effect is an intense appetite surge, with onset 15–30 minutes post-injection and a duration of approximately 30–60 minutes. At doses above 100–200 mcg, cortisol and prolactin elevation become noticeable and can interfere with sleep and stress recovery. Rare effects include gynecomastia or lactation (prolactin-mediated). Do not use with active cancer due to the GH/IGF-1 and CD36 angiogenesis concern.
Can GHRP-6 be taken orally?
No. Oral bioavailability is below 1%. Frieboes et al. (1999) showed that oral GHRP-6 at 300 mcg/kg produced no GH response in adults due to DPP-4 enzymatic degradation and first-pass liver metabolism. An effective oral dose would theoretically require 20,000–40,000 mcg versus 100–300 mcg injectable. Oral GHRP-6 products are not effective regardless of price.
What is the best GHRP-6 stack for muscle growth?
GHRP-6 + CJC-1295 No DAC (100 mcg each, 2–3× daily, fasted) is the most widely used combination. Different receptor mechanisms produce documented synergistic GH amplification — approximately 3–4× more GH than either peptide alone (Teichman et al., 2006, PMID 16352683). For injury recovery applications, BPC-157 (250–500 mcg, 1–2× daily) is commonly added, though the injury evidence for BPC-157 is animal data.
Does GHRP-6’s GH response decline with age?
No. Popovic et al. (1995, PMID 7734029) demonstrated that GHRP-6-induced GH release is preserved with age, unlike the GHRH response which declines. This finding suggests that age-related GH reduction may reflect a functional state rather than permanent loss of pituitary capacity — which is the basis for interest in GHRP-6 in anti-aging contexts.
Considering peptide therapy? Speak with a licensed physician who can review your labs and discuss whether any protocol is appropriate for your situation.
References
- Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537–1545.
- Lei T, Buchfelder M, Fahlbusch R, Adams EF. Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells. J Mol Endocrinol. 1995;14(1):135–138. PMID: 7772238.
- Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186–1189. PMID: 9543138.
- Popovic V, Damjanovic S, Micic D, et al. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection. J Clin Endocrinol Metab. 1995;80(3):942–947. PMID: 7734029.
- Cabrales A, Gil J, Fernández E, et al. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013;48(1-2):40–46. PMID: 23099431.
- Frieboes RM, Murck H, Stalla GK, Antonijevic IA, Steiger A. Enhanced slow wave sleep in patients with prolactinoma. J Clin Endocrinol Metab. 1998;83(8):2706–2710.
- Berlanga-Acosta J, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Cardiol. 2017;11:1179546817694558.
- Berlanga-Acosta J, et al. [2024 cardioprotection study]. PMID: 38873581.
- Granado M, et al. GHRP-6 prevents hepatic and intestinal damage in ischemia/reperfusion model. J Endocrinol. 2005;187(3):325–336. PMID: 16417467.
- Pimentel-Filho FR, et al. Effect of GH-releasing peptide-6 on GH secretion in hypothyroid patients. Clin Endocrinol. 1997;46(3):295–299.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799–805. PMID: 16352683.
- WADA 2025–2026 Prohibited List. Section S2.2: Growth Hormone Secretagogues.
Disclaimer: PeptideRx provides physician-reviewed educational content about peptide therapy. PeptideRx does not provide medical advice, diagnosis, or treatment. GHRP-6 is not FDA-approved for human therapeutic use. GHRP-6 is explicitly prohibited by WADA under S2.2 at all times. All dosing information reflects published research protocols and community-reported practices, not prescribing recommendations. Consult a licensed healthcare provider before making any decisions about peptide therapy.